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Huntington’s disease (HD) is a fatal neurodegenerative condition caused by expansion of the polyglutamine tract in
the huntingtin (Htt) protein. Neuronal toxicity in HD is thought to be, at least in part, a consequence of protein
interactions involving mutant Htt. We therefore hypothesized that genetic modifiers of HD neurodegeneration should
be enriched among Htt protein interactors. To test this idea, we identified a comprehensive set of Htt interactors using
two complementary approaches: high-throughput yeast two-hybrid screening and affinity pull down followed by mass
spectrometry. This effort led to the identification of 234 high-confidence Htt-associated proteins, 104 of which were
found with the yeast method and 130 with the pull downs. We then tested an arbitrary set of 60 genes encoding
interacting proteins for their ability to behave as genetic modifiers of neurodegeneration in a Drosophila model of HD.
This high-content validation assay showed that 27 of 60 orthologs tested were high-confidence genetic modifiers, as
modification was observed with more than one allele. The 45% hit rate for genetic modifiers seen among the
interactors is an order of magnitude higher than the 1%–4% typically observed in unbiased genetic screens. Genetic
modifiers were similarly represented among proteins discovered using yeast two-hybrid and pull-down/mass
spectrometry methods, supporting the notion that these complementary technologies are equally useful in identifying
biologically relevant proteins. Interacting proteins confirmed as modifiers of the neurodegeneration phenotype
represent a diverse array of biological functions, including synaptic transmission, cytoskeletal organization, signal
transduction, and transcription. Among the modifiers were 17 loss-of-function suppressors of neurodegeneration,
which can be considered potential targets for therapeutic intervention. Finally, we show that seven interacting
proteins from among 11 tested were able to co-immunoprecipitate with full-length Htt from mouse brain. These
studies demonstrate that high-throughput screening for protein interactions combined with genetic validation in a
model organism is a powerful approach for identifying novel candidate modifiers of polyglutamine toxicity.
Citation: Kaltenbach LS, Romero E, Becklin RR, Chettier R, Bell R, et al (2007) Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 3(5): e82.
doi:10.1371/journal.pgen.0030082
Introduction
Huntington’s Disease (HD) is a member of a family of
dominantly inherited neurodegenerative diseases caused by
expansion in a glutamine-encoding CAG tract. HD occurs
when the polyglutamine (polyQ) tract in huntingtin (Htt)
expands beyond ;35 glutamine (Q) repeats and manifests
with movement disorder, psychological disturbances, and
cognitive dysfunction progressing over a period of about ten
to 15 years until death. Currently there is no effective
treatment or cure for HD.
Mutant Htt is thought to cause cellular dysfunction,
neurodegeneration, and associated clinical features primarily
through a toxic gain of functi o n[ 1 ] .I n d e e d ,p r o t e i n s
containing expanded polyQ tracts are toxic when expressed
in a wide range of experimental transgenic systems including
yeast, cultured mammalian cells, Caenorhabditis elegans, Droso-
phila, and mouse [2–4]. Determining the precise mechanism of
polyQ-mediated toxicity is a subject of intense inquiry, and
there is evidence supporting a role for aberrant protein-
protein interactions in pathogenesis. In HD, expanded Htt is
processed to N-terminal fragments that form inclusions
found both in the cytoplasm and nucleus [5,6]. A number of
proteins localize to expanded polyQ inclusions, including
ubiquitin/proteasome components, heat shock proteins, and
transcription factors [7–12]. These ﬁndings support the idea
that mutant Htt may interfere with the functions of diverse
cellular proteins directly, through protein interactions. Some
interacting proteins have been shown to be functionally
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addition, some of these proteins localize to insoluble Htt-
fragment-containing inclusions present in affected tissues
[15,16]. Recent work, however, has suggested that inclusions
may be benign or even protective and that other misfolded
forms of Htt may be the primary toxic species [17–19]. Since
interactions between cellular proteins and soluble or aggre-
gated Htt may have a general role in HD pathogenesis,
identiﬁcation of Htt-interacting proteins will further eluci-
date toxic mechanisms and therapeutic targets for the
disease.
Htt is a large, ubiquitously expressed protein comprised
nearly entirely of HEAT repeats, a characteristic protein-
protein interaction motif [20,21]. Nearly 50 proteins capable
of interacting directly with Htt or Htt fragments have been
described. Most proteins have been found to interact with N-
terminal polyQ containing Htt fragments and, in some cases,
the strength of these interactions has been shown to be
sensitive to the length of the polyQ tract [22,23]. Htt-
interacting proteins represent diverse cellular roles including
intracellular transport, transcription, and ubiquitin-medi-
ated proteolysis. These observations suggest that the normal
function of Htt involves multiple protein-protein interac-
tions in the context of diverse multiprotein cellular com-
plexes. Indeed, loss of normal Htt function is a component of
HD pathology [24]. Identifying Htt protein-protein inter-
actions may help to elucidate the functions of wild-type Htt
as well as the novel gain of function of mutant Htt.
In this study we report a large set of novel Htt-fragment-
interacting proteins using yeast two-hybrid (Y2H) and afﬁnity
pull-down/mass spectrometry (MS) protein interaction
screens. We used both approaches in parallel in an effort to
deﬁne a comprehensive set of interactors, as there is evidence
that each method explores different groups of interacting
proteins [25–28]. We reasoned that if expanded Htt can
inﬂuence the functions of its interacting proteins (and vice
versa), genes encoding interacting proteins should be
enriched for genetic modiﬁers of neurotoxicity mediated by
expression of a mutant Htt fragment. We used a Drosophila
model of polyQ toxicity to test this idea and found that 45%
of the interactors behave as high-conﬁdence genetic modi-
ﬁers (i.e., interaction conﬁrmed with more than one allele).
Importantly, protein interactions validated as genetic modi-
ﬁers in Drosophila were equally represented in the Y2H and
MS derived datasets, demonstrating the complementary
nature of these independent methods.
A standard method for validation of large-scale interaction
datasets relies on co-afﬁnity precipitation of samples of the
protein interaction pairs [29,30]. Whereas co-afﬁnity precip-
itation does conﬁrm a physical interaction, it does not
establish the biological relevance of that interaction. The
high-content validation method used in this study (genetic
interaction in a whole organism) strongly supports the
conclusion that this dataset is highly enriched for interacting
proteins with functional roles in polyQ-mediated neuro-
degeneration. Using co-immunoprecipitation, we show fur-
ther that a number of these modiﬁer proteins physically
associate with Htt in brain tissue of transgenic mice
expressing full length Htt protein.
An ultimate result of this study is to provide insight into
potential therapeutic targets for HD. The 17 loss-of-function
suppressors of Drosophila HD reported here constitute a
signiﬁcant collection of novel targets (and pathways) to be
considered as targets for therapeutic intervention.
Results
Identification of Novel Htt-Fragment-Interacting Proteins
In a comprehensive search for novel Htt-fragment-inter-
acting proteins, we performed two large-scale screens for
interactions using MS and Y2H methods (Figure 1A). Multiple
fragments of Htt, including both wild-type and mutant N-
terminal fragments, were cloned and expressed for pull-down
experiments and Y2H screens (Figures 1B and S1). We
puriﬁed ﬁve recombinant Htt-fragment baits (corresponding
to amino acid residues 1-90-23 Q, 1-90-48 Q, 1-90-75 Q, 443–
1,100, and 2,758–3,114) from Escherichia coli in sufﬁcient
quantities for pull-down experiments. A total of 97 pull-down
experiments were performed with these Htt-fragment baits
and mammalian tissue or cell protein lysates (Figure 1).
Tandem afﬁnity puriﬁcation (TAP)-tagged Htt-fragment
containing protein complexes were allowed to form in
protein extracts prepared from mouse or human brain tissue
or mouse muscle tissue. Complexes were copuriﬁed with the
afﬁnity tagged Htt-fragment proteins and analyzed by MS. Of
the ﬁve Htt-fragment bait proteins, only the 1–90 amino
terminal fragments yielded speciﬁc and reproducible protein
complexes. The wild-type and mutant Htt-fragment baits
(corresponding to exon 1 of the HD gene) (Figure 1B) were
also used to probe protein extracts prepared from cultured
cells (HEK293, HeLa, and M17 neuroblastoma). Using the
database-searching tool MASCOT, we generated a primary
dataset of 1,107 unique high-scoring peptides present in the
Htt-fragment pull downs (Figure 1A; Table S1). To generate a
high-conﬁdence interaction list, we subjected these peptides
to a statistical test for speciﬁc association with Htt fragments
by comparison to a database of 15,131 high-scoring peptides
identiﬁed in pull downs performed with 88 different protein
baits (unpublished data). This analysis was used to generate a
p-value for the association of a particular peptide with Htt-
fragment pull downs. A total of 410 unique peptides from
Htt-fragment pull downs met a p-value limit of  0.05, and
each of these peptides was manually validated by inspection
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Author Summary
Huntington’s Disease (HD) is a fatal inherited neurodegenerative
disease, which typically begins in middle age and progresses with
symptoms of severe uncontrolled movements and cognitive
dysfunction. HD is uniformly fatal with death occurring ten to 15
years after onset of symptoms. There is currently no effective
treatment for HD. The genetic mutation underlying HD causes a
protein called huntingtin (Htt) to contain an abnormally long tract of
the amino acid glutamine. This extended span of glutamines
changes the shape of the Htt protein, which can cause it to interact
in abnormal ways with other cellular proteins. In this study, we have
identified a large number of new proteins that bind to normal and
mutant forms of the Htt protein. To establish a potential role for
these interacting proteins in HD, we show that changing the
expression of many of these proteins can modulate the pathological
effects of mutant Htt on fly neurons that deteriorate when they
express mutant Htt. Identifying cellular proteins that bind to Htt and
modulate its pathological activity may facilitate the discovery of an
effective treatment for HD.of the MS spectra (see detailed methods in Supporting
Information). The data were ﬁltered further by excluding any
proteins identiﬁed by peptides observed in control pull
downs with TAP-tag alone or proteins containing any
peptides not meeting the p-value cut-off (i.e., peptides not
speciﬁc to Htt-fragment pull downs). These methods identi-
ﬁed 145 mouse and human proteins speciﬁc to Htt-fragment
pull downs and eliminated many proteins considered to be
false positives in other studies (Tables 1 and S1) [25]. Genes
encoding orthologs of 28 of these proteins were tested for
genetic interaction with a truncated mutant N-terminal
human HD gene in a Drosophila model of polyQ toxicity.
In addition to solution-based MS protein interaction
studies, we performed Y2H searches with Htt-fragment baits
using a high-throughput automated screening platform [31].
A total of 3,749 individual Y2H searches of HD fragment baits
were performed against prey libraries prepared from 17
different human tissue cDNA sources (Figure 1). Multiple
overlapping baits were searched extensively but only baits
located near the Htt N terminus (including polyQ containing
fragments) gave reproducible interactions (Figure 1B, solid
lines). PolyQ containing Htt-fragment baits of amino acids 1–
90, 1–450 or 1–740 were screened in both wild-type (23 Q)
and mutant (.45 Q) forms. Screens were performed under
stringent selection conditions requiring simultaneous activa-
tion of two independent auxotrophic reporter genes, HIS3
and ADE2 [31,32]. Initial results identiﬁed a total of 562
unique interacting prey proteins (Figure 1A; Tables S2 and
S3). Because Y2H screens have been estimated to contain up
to 50% false positives among the primary positives [33,34],
the data were ﬁltered using stringent criteria to eliminate
false positives and generate a high-conﬁdence dataset. First,
only interactions that had been independently observed at
least three times in Y2H screens were included. Next,
proteins were excluded if they were observed to interact
with more than 174 unique partners in a database of 110,000
interacting protein pairs generated from approximately
290,000 Y2H screens. These searches were performed in a
large random screen for human protein interactions (un-
published data). This cut-off, designed to eliminate promis-
cuous interactors, was calculated by k-means clustering
analysis of the random dataset [31]. Finally, genes encoding
interacting preys were recovered from positive yeast colonies,
sequenced twice, and reintroduced with Htt-fragment bait
into naive Y2H assay cells. Genes were excluded if the
interaction with Htt fragments could not be reproduced in
the Y2H assay (as measured by activation of two reporter
genes). Previously published Htt and Htt-fragment interac-
tors were included in the ﬁnal list regardless of the exclusion
criteria. A total of 104 unique interacting proteins (18% of
the primary dataset) met these conditions and were included
in the ﬁnal high-conﬁdence dataset (Table 2). A complete list
of all Htt-fragment interactions found in our Y2H screens is
shown in Table S2. Sequences derived from all positive
colonies used to identify the interacting proteins are
presented in Table S3. Orthologs of 35 of these genes were
tested for genetic interactions with a mutant human N-
terminal portion of the HD gene in a Drosophila model of
polyQ toxicity.
While more than 3,500 searches were performed with Htt
fragments, after 800 searches the rate of discovery for novel
interacting proteins approached zero, indicating that these
screens were close to saturation (Figure S2). This result
demonstrates that the total number of Htt-fragment-inter-
acting proteins discovered in our Y2H screens represents a
ﬁnite set and is not simply a function of the number of
searches.
Examining the gene ontology annotations associated with
Figure 1. Results of the Physical Interaction Screens
(A) Overview of the discovery workflow is represented. Y2H and pull-
down/MS workflows are shown on the left and right, respectively. The
number of Htt-fragment baits used for Y2H searches or pull downs
includes wild-type (23 Q) and mutant (48 Q and 55 Q) forms. Not all Htt
fragments were successfully expressed in bacteria or yielded positive
interactions in Y2H screens. For Y2H positive prey identification, the top
blast score was chosen. The total number of genes found in pull down/
MS includes 15 mouse and human homologs; the nonredundant set
does not include mouse homologs (see Supporting Information).
(B) A diagram of Htt baits used in Y2H and MS experiments is presented.
Structural features (HEAT repeat domains and protease cleavage region)
are indicated by shaded boxes on a diagram of the Htt protein. Numbers
indicate reference amino acids positions (with respect to NP_002102).
Lines representing Htt-fragment baits with associated amino acid
positions indicated by numbers are shown relative to the diagram of
Htt. We purified three Htt-fragments (top panel) from bacteria in
sufficient quantities for pull-down/MS experiments. Htt-fragment baits
used in Y2H screens are shown on the bottom panel. Some baits did not
yield positive interactions (dotted lines). Htt clones that contained the
polyQ sequence were generated in wild-type (23 Q) and expanded (55 Q,
75 Q, and 97 Q) forms (asterisk).
(C) A functional analysis of Htt-fragment-interacting proteins is
presented. The number of proteins representing the indicated functional
categories found in Htt-fragment Y2H screens (white bars) or pull down/
MS (black bars) are shown. Proteins were assigned to categories based
on gene ontology. Only categories with more than one protein assigned
are shown.
doi:10.1371/journal.pgen.0030082.g001
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Huntingtin Interactomeinteracting proteins reveals that the two methods differ to
some degree in the type of proteins identiﬁed (Figure 1C).
Y2H clearly identiﬁed more proteins involved in protein
turnover, signal transduction, and transcription, while MS
identiﬁed more proteins involved in metabolic processes.
However, proteins involved in cytoskeletal or protein-
trafﬁcking processes were similarly represented among the
Y2H and MS data. Overall, there was little overlap of speciﬁc
interacting proteins between the two datasets. Only four
high-conﬁdence proteins were found using both methods:
clathrin, pyruvate kinase, GAPDH, and YWHAB (Tables S1
and S2). Two of these, clathrin and GAPDH have been
previously reported to associate with Htt fragments [35,36].
To directly address the biological relevance of the Htt-
fragment protein-interaction dataset and to assess the
relative validity of results generated using the Y2H and MS
methods, we tested a sample of interacting proteins in a high-
content independent method, a genetic modiﬁer assay in a ﬂy
model of polyQ toxicity.
Validation of Htt-Fragment-Interacting Proteins in a
Drosophila Model of PolyQ Toxicity
An arbitrary sample of 60 proteins in the dataset was
tested for the ability to modify an Htt-fragment-induced
neurodegeneration phenotype in Drosophila.T h i sp o l y Q
toxicity model was generated using an N-terminal fragment
of the human HD cDNA, encoding the ﬁrst 336 amino acids
of the protein, including a 128 Q expansion in exon 1 (see
Materials and Methods). Directed expression of this ex-
panded human HD transgene fragment in the Drosophila eye
causes a neurodegenerative phenotype evident by external
examination and retinal histology. Of the 234 nonredundant
mammalian protein interactors found in the MS and Y2H
screens, 213 had apparent orthologs in Drosophila (unidirec-
tional top hit with BLAST score less than 10
 3), and 127 of
these had available Drosophila stocks suitable for screening.
We tested 60 of these, divided roughly equally between genes
discovered using Y2H (35) and MS (28) methods (including
three genes found in common), for possible genetic
interactions in the ﬂy model of polyQ toxicity (Table S4). A
total of 48 of the 60 genes in the sample (80%) either
enhanced or suppressed the expanded Htt-fragment-induced
neurodegeneration in the Drosophila eye when tested in
either over-expressing or in partial loss-of-function strains
(Tables 3 and S5). In some cases a modiﬁer effect was
observed, but only one background strain could be tested
(Table S5). However, for 27 of these genes, modiﬁcation
either by more than one allele or in more than one genetic
background was observed. These genes comprise a high-
conﬁdence set of genetic modiﬁers of mutant Htt-fragment
toxicity (Figures S3 and S4; Table 3). The 27 high-conﬁdence
modiﬁers represent a 45% validation rate among those
interactors tested. Since the collection of genes tested in the
ﬂy assay represented an arbitrary sample of the protein
interaction collection, this result indicates that as much as
half of the proteins in our dataset may be modiﬁers of
mutant Htt toxicity. The hit rate for genetic modiﬁers seen
among our interactors is an order of magnitude higher than
the expected 1%–4% typically observed in unbiased genetic
screens [37–39], including a comparable modiﬁer screen
using a Drosophila model of the polyQ disease spinocerebellar
ataxia type 1 [40]. Validation rates for proteins discovered by
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Huntingtin Interactomeeither Y2H (27/35 or 77%) or MS (21/28 or 75%) methods
were similar, indicating that these methods are comparable
in their ability to uncover biologically relevant interactions
(Table 3). These relative validation rates demonstrate further
that the MS and Y2H datasets are complementary in nature
and that each dataset is similarly enriched for genes and
proteins that modify mutant Htt toxicity in vivo. Further-
more, the majority of these modiﬁers were discovered in
interaction screens performed with human brain protein
extracts or brain-derived cDNA libraries indicating that they
are expressed in tissues relevant to HD (Tables 1 and 2).
Among the 27 high-conﬁdence modiﬁers, partial loss-of-
function mutations were tested for 27 of them and over-
expression mutations for nine. A total of 18 of the modiﬁers
behaved as suppressors of neurodegeneration, (14 by partial
loss-of-function and four by over-expression) (Figure S3),
whereas 18 behaved as enhancers (13 by partial loss-of-
function and ﬁve by over-expression) (Figure S4). In all 13
cases where both over-expression and loss-of-function alleles
were tested, suppression was observed in one condition and
enhancement in the other. These modiﬁers cluster into
several functional groups including proteins involved in
cytoskeletal organization and biogenesis, signal transduction,
synaptic transmission, proteolysis, and regulation of tran-
scription or translation (Table 3). Histological analysis of eye
phenotypes from representative enhancers and suppressors
from each of these groups is shown (Figure 2).
One interesting subset of modiﬁers is a group of proteins
involved in SNARE-mediated vesicle fusion [41,42]. This
includes STX1A, NAPA, and the voltage-gated calcium
channel delta subunit CACNA2D1. Interestingly, alleles
encoding all of these proteins act both as loss-of-function
suppressors and gain-of-function enhancers in the ﬂy assay.
Collectively, these modiﬁer results point toward a model of
Htt toxicity involving dysregulation in synaptic function at
the level of SNARE-mediated vesicle fusion.
Additional experiments were performed to further validate
a role for a SNARE component in modifying mutant Htt
toxicity (Figure 3). In contrast to expression in the eye, pan-
neural expression of N-terminal expanded Htt leads to a
shortened lifespan in the ﬂy model of polyQ toxicity. Pan-
neural expression also results in late-onset progressive motor
dysfunction that can be quantiﬁed in terms of climbing
performance as a function of age. These behavioral assays
conﬁrm the results obtained in the eye assay: partial loss-of-
function of STX1A ameliorates both the disorganization and
fusion of ommatidia seen in ﬂies expressing the gene that
encodes N-terminal expanded Htt as well as the retinal
degeneration. The shortened life-span and the late-onset
progressive motor dysfunction phenotypes were also im-
proved by a partial loss-of-function of STX1A, conﬁrming
that the modiﬁer effects seen in the eye were not limited to a
particular phenotypic assay (Figure 3B and 3C). Htt is known
to interact with proteins involved in endocytosis and vesicle
trafﬁcking such as PACSIN1, HAP1, HIP1, and HIP14 [22],
however, this is the ﬁrst report showing that Htt interacts
directly with the SNARE complex and that partial loss-of-
function can suppress mutant Htt toxicity.
A network summarizing interactions relevant to Htt and
proteins with gene ontology annotations (http://www.
geneontology.org) related to vesicle trafﬁc and/or neuro-
transmission is shown in Figure 4. Included here are Y2H
interactions (rectangles and thick lines) and proteins identi-
ﬁed by MS (ovals) in pull downs using lysates prepared from
mouse and/or human brain tissue (set included in dotted
circle). A total of 11 proteins in this interaction subnetwork
(shown in red) are encoded by human orthologs of genes
shown to act as modiﬁers in the Drosophila model of polyQ
toxicity (Tables 3 and S3). Notably, several modiﬁers are
present in a highly connected cluster of Htt-fragment-
interacting proteins known to function in receptor-mediated
endocytosis: CLTC, AP2A2, AP2B1, PACSIN1, and DNM1.
The observations that Htt is localized to endosomal vesicles
and associated with clathrin in ﬁbroblasts derived from HD
patients [5,43] and that vesicle associated proteins are found
in Htt-fragment inclusions [44] makes this interconnected
cluster of modiﬁers particularly striking. Curated Htt-frag-
ment-interacting proteins obtained from BioGRID (http://
www.thebiogrid.org) [45] and/or the Human Protein Refer-
ence Database (http://www.hprd.org) [46,47] are included in
the network. These bridging proteins (blue triangles) repre-
sent all curated interactions contained in these databases that
connect HD to at least one other protein in the subnetwork
though a single protein node and link some of our novel Y2H
interactions and MS associations to known Htt-interacting
proteins (e.g., HIP1, GIT1). Together, this interaction network
provides additional proof that our dataset is enriched for
proteins that are important in HD pathogenesis and under-
scores the role of proteins involved in vesicle trafﬁc as being
relevant to HD function and pathology.
Validation of Htt-Fragment-Interacting Proteins Using
Immunoprecipitation
For further in vivo validation of Htt-fragment protein
interactions in mammalian tissue, we performed co-immu-
noprecipitation experiments from brains of wild-type mice
and mice expressing a 128 Q full length YAC transgene [48].
Figure 5 shows the results of co-immunoprecipitation experi-
ments using antibodies raised against Htt-fragment-interact-
ing proteins. In all, we observed co-immunoprecipitation
with seven of 11 interacting proteins tested. These included
the SNARE-associated proteins STX1A and CACNA2D1, both
of which are modiﬁers in the Drosophila assay. We also
observed co-immunoprecipitation with SNAP25 (another
SNARE component). Other modiﬁers observed to associate
with Htt in mouse brain were the ubiquitin hydrolase USP9X
and the proteasome component PSMC2. None of these
interacting proteins appeared to show a strong preference
for wild-type versus CAG expanded Htt in this assay.
Immunoprecipitation using antibodies directed against
GAPDH and PARP are included as positive and negative
controls. We observed a polyQ length-dependent association
of GAPDH with Htt. The GAPDH protein has been reported
to bind Htt and act as a modiﬁer of mutant Htt toxicity
[36,49].
Overall, in this sample, we observed a 60% validation rate
in this assay (seven of 11 proteins tested). Of the seven
proteins observed to co-immunoprecipitate with Htt from
mouse brain, three were discovered using Y2H (CUL2,
PSMC2, and USP9X), two were discovered using MS (STX1A
and SNAP25), and one by both methods (PKM2). This further
underscores a speciﬁc utility of both methods for discovery of
interacting proteins.
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Huntingtin InteractomeDiscussion
Although the gene encoding Htt was identiﬁed over a
decade ago, the normal function of this protein and the
precise mechanisms by which expanded polyQ exerts its toxic
effects remain the subjects of intense inquiry. In this study we
identiﬁed 234 potential new Htt-associated proteins using
high-throughput proteomic screens. The diverse functions of
Htt and Htt-fragment protein partners and modiﬁers
reported here are consistent with the functional diversity of
pathogenic processes and targets in HD. Htt is localized to a
number of different cellular compartments, and there is a
large body of evidence showing that mutant Htt fragments
can interfere with a diverse range of proteins and pathways
including, transcriptional activation and co-activation
[12,13,15], ubiquitin-mediated proteolysis [50], mitochondrial
energy metabolism [51,52], receptor-mediated signal trans-
duction [53], axonal transport [54], and vesicle trafﬁcking
[43,44]. These observations suggest models of Htt-mediated
pathology that involve interference in multiple cellular
pathways.
Furthermore, we have identiﬁed a novel association
between Htt fragment and components of the vesicle
secretion apparatus (Table 1). Stx1A, NAPA, and CACNA2D1
were conﬁrmed as modiﬁers in the ﬂy polyQ toxicity model
(Table 3), and SNAP25, STX1a, and CACNA2D1 proteins
were observed to co-immunoprecipitate with full length Htt
from mouse brain (Figure 5). Protein interactions and
localization experiments have placed Htt primarily at
postsynaptic sites (reviewed in [55]), but Htt has also been
shown to be associated with N-type calcium channels in
presynaptic cells [56]. These results suggest that modulation
of SNARE-mediated neurotransmitter secretion may be a
normal function for Htt and/or may be perturbed by mutant
Htt.
In addition to the general large-scale protein interaction
screens reported for human proteins, two screens have been
reported that focus speciﬁcally on proteins related to polyQ
disease. A large-scale Y2H screen for Htt-fragment binding
proteins uncovered 15 novel interacting proteins, including
GIT1, an enhancer of polyQ aggregation [57]. A more recent
screen for protein interactions relevant to inherited ataxias
reported a large network of interaction involving 54 proteins
implicated in human ataxia [29]. Interestingly, there was more
overlap between high-conﬁdence interactions in our dataset
and the previously published Htt dataset [57] than the ataxia
dataset [29], suggesting that protein-protein interactions may
contribute to pathogenic speciﬁcity found among the polyQ
diseases. Validation of interactions in the ataxin network
study relied on demonstration of co-afﬁnity precipitation of
Figure 2. Modification of the Phenotypes Caused by N-Terminal Expanded Htt in the Drosophila Eye
Retinal sections of adult Drosophila eyes show modification of the phenotypes caused by expression of different levels (B and I) of a transgene encoding
an N-terminal expanded Htt fragment. Enhancers (C–G) and suppressors (J–N) include proteins involved in cytoskeletal organization (C) and (J), signal
transduction (D) and (K), neurotransmitter secretion (E) and (L), proteolysis/peptidolysis and the ubiquitin cycle (F) and (M), and transcriptional/
translational regulation (G) and (N). Retinal sections of day 5 control flies cultured at 25 8C expressing the gene that encodes expanded N-terminal Htt
fragment (GMR-GAL4/þ; UAS:128Qhtt[M64]/þ) (B) show a degenerative phenotype when compared to controls of the same age and cultured at the same
temperature (GMR-GAL4/þ) (A). The phenotype consists of a shortening (see arrow) and detachment of the retina, as well as the presence of vacuoles in
the retina. The Htt-fragment-induced phenotype can be enhanced by (C) reduced levels of zipper (GMR-GAL4/PfPZgzip
02957; UAS:128Qhtt[M64]/þ), (D)
reduced levels of Src oncogene at 42A (GMR-GAL4/PflacWgSrc42A
k10108; UAS:128Qhtt[M64]/þ), (E) overexpression of soluble N-ethylmaleimide-sensitive
-attachment protein (GMR-GAL4/þ; UAS:128Qhtt[M64]/UAS-S102C#2D), (F) reduced levels of fat facets (GMR-GAL4/þ; UAS:128Qhtt[M64]/faf
Bx4), and (G)
reduced levels of crooked legs (GMR-GAL4/PfPZgcrol
04418cn
1; UAS:128Qhtt[M64]/þ). None of these mutations cause an abnormal eye phenotype in flies
carrying the GMR-GAL4 driver but not the UAS:128Qhtt[M64] transgene (unpublished data). However, when combined with an N-terminal expanded Htt
fragment, they lead to an even larger decrease in retinal thickness sometimes accompanied by an increase in retinal detachment and vacuolization.
Retinal sections of day 1 control flies cultured at 27 8C expressing a gene that encodes an expanded N-terminal Htt fragment (GMR-GAL4/þ;
UAS:128Qhtt[M64]/þ) (I) show a severe degenerative phenotype when compared to GMR controls of the same age and cultured at the same
temperature (H). The phenotype consists of a shortening (see arrow) and detachment of the retina, as well as the presence of vacuoles in the retina.
The Htt-fragment-induced phenotype can be suppressed by (J) reduced levels of hu li tai shao (GMR-GAL4/PflacWghts
k06121; UAS:128Qhtt[M64]/þ), (K)
reduced levels of G protein iasubunit 65A (GMR-GAL4/; UAS:128Qhtt[M64]/PfSUPor-PgG-ia65A
KG01907ry
506), (L) reduced levels of clathrin heavy chain
(Chc
1/þ GMR-GAL4/þ; UAS:128Qhtt[M64]/þ), (M) reduced levels of Rpt1 (GMR-GAL4/PfPZgRpt1
05643cn
1; UAS:128Qhtt[M64]/þ), and (N) reduced levels of
myocyte enhancing factor 2 (GMR-GAL4/Df(2R)X1,Mef2[X1]; UAS:128Qhtt[M64]/þ). These mutations decrease the vacuolization and increase the retinal
thickness as well as virtually eliminating the retinal detachment.
doi:10.1371/journal.pgen.0030082.g002
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Huntingtin Interactometagged expressed protein pairs. Here we tested the ability of a
genetic model to validate protein interactions. 48 of 60 genes
tested in a polyQ-induced ﬂy eye degeneration model of HD
modiﬁed the polyQ-induced toxicity, suggesting that this list
contains protein interactors that also genetically interact
with Htt. Our validation rate using the Drosophila genetic
model (80%) is similar to that found using co-afﬁnity
puriﬁcation in the ataxia and Htt studies (80% and 65%,
respectively) [29,57]. Moreover, whereas co-afﬁnity puriﬁca-
tion gives validation of the physical interaction of proteins,
the genetic modiﬁcation screen provides additional informa-
tion suggesting a biological role in genetic pathways relevant
to HD. Overall, these observations demonstrate the utility of
combining protein-interaction screening with genetic-inter-
action screening to provide insight into disease mechanisms
and identify potential targets for therapeutic intervention.
Whereas our datasets more than quadruple the potential
number of interactions attributed to Htt or Htt fragments,
the in vitro derived interactor datasets do contain non-
relevant interactions (false positives) and do not represent all
binding proteins (false negatives), an issue common to high-
throughput screens. For example, despite the saturation of
the screens we identiﬁed some, but not all, of the known Htt-
fragment-interacting proteins. Our protein interaction
screens revealed 14 of the 40 interactions previously
discovered using Y2H methods [22,23]. Using different Y2H
methods, a recent high-throughput screen isolated 19 Htt-
fragment-interacting proteins, four of which had been
previously described [57]. Together, these data suggest that
different Y2H methods yield overlapping but not identical
datasets, likely due to differences in selection stringency as
well as other technical differences. Surprisingly, only Htt
Figure 3. Modification of the Expanded Htt-Fragment-Induced Phenotype by a STX1A Loss-of-Function Mutation
Modification was observed both in the eye (external phenotype and retinal sections) and in the nervous system (climbing ability and survival).
(A) Retinal sections of day 5 flies raised at 25 8C (left), day 1 flies raised at 27 8C (middle), and standard error of mean of day 5 flies raised at 29 8C (right)
expressing a gene that encodes expanded N-terminal Htt fragment (GMR-GAL4/þ; UAS:128Qhtt[M64]/þ).
(B) Retinal sections of day 5 flies raised at 25 8C (left), day 1 flies raised at 27 8C (middle), and standard error of mean of day 5 flies raised at 29 8C (right)
expressing a gene that encodes expanded N-terminal Htt fragment and carrying reduced levels of STX1A (GMR-GAL4/þ; UAS:128Qhtt[M64]/
Syx1A229ry506). Note suppression of both the retinal and external eye phenotypes at all three temperatures. Overexpression of STX1A shows
enhancement of the retinal degeneration and external 128 Qhtt phenotype (unpublished data).
(C) Climbing assay (top) and survival assay (bottom) results confirm the suppression observed in the eye assay. Shown in red/pink are the climbing
performance and survival curve of a population of females flies expressing a gene that encodes expanded N-terminal expanded Htt fragment (elav-
GAL4/þ; UAS:128Qhtt[F27B]/þ). Shown in blue/light blue are the improved climbing performance and survival curve of a population of females flies
expressing a gene that encodes expanded N-terminal Htt fragment and carrying a heterozygous loss-of-function mutation in STX1A (elav-GAL4/þ;þ/þ;
UAS:128Qhtt[F27B]/Syx1A229 ry506). (x-Axis, age of flies in days; y-axis, percent surviving or climbing flies; LOF, loss-of-function).
doi:10.1371/journal.pgen.0030082.g003
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Huntingtin Interactomefragments near the N terminus of the protein were able to
generate reproducible protein interaction in our Y2H
screens (Table 2). This ﬁnding is consistent with a previous
report in which Y2H methods failed to detect interactions
from Htt-fragment baits outside the amino terminus [58] and
may be in part due to technical limitations of the Y2H
method. For example, C-terminal Htt fragments may not fold
properly in yeast, may require post-translational modiﬁca-
tions not found in yeast for interaction with protein partners,
or may be localized away from the nucleus. Even fewer known
Htt-interacting proteins were found by pull-down/MS meth-
ods. Interestingly, the cytosolic chaperonin-containing t-
complex (CCT or TriC) was recently shown to physically
interact with Htt and modify the course of polyQ-induced
toxicity in mammalian cells [59,60]. We found that two
components of the CCT complex, CCT6 and CCT8, were
associated with Htt exon1 in pull downs. Together, these data
suggest that many potential Htt-interacting or Htt-associated
proteins remain to be discovered by other methods.
Overall, there was little overlap between interactions found
by the Y2H and pull-down methods (4/234). This low degree
of overlap is consistent with results seen in other systems-
scale protein interaction datasets generated using Y2H and
MS methods. For example, interaction screens of the yeast
proteome using Y2H (4,476 and 915 binary protein inter-
actions) [27,28] and MS-based screens (3,767 and 3,727
interactions in proteins complexes) [25,26] yielded a 2%–
5% overlap. It has been suggested that this low overlap
between interaction screening methods may arise from
several factors including method-speciﬁc biases [34]. Ulti-
mately, the value of protein interaction data generated by any
method needs to be evaluated through experimental vali-
dation. We clearly demonstrate here that both methods are
similarly capable of identifying Htt-fragment-interacting
Figure 4. A Network of Protein Interactions Involved in Vesicle Traffic
A network is shown that includes protein interactions described in this
study and interactions curated from the public domain (NCBI Entrez
Gene). Htt-fragment-interacting proteinss found in this study are
indicated as ovals (MS) or rectangles (Y2H). Binary Y2H interactions
found in this study are indicated as thick lines. Proteins contained in the
dotted circle were identified in Htt-fragment pull downs using brain
lysates. Thin lines indicate curated protein interactions. Curated bridging
interactions (blue triangles) are defined as proteins reported to interact
with HD and at least one other protein in the network. Proteins whose
Drosophila ortholog genes acted as modifiers in this study are indicated
in red.
doi:10.1371/journal.pgen.0030082.g004
Figure 5. Co-Immunoprecipitation of Huntingtin-Interacting Proteins
from YAC128 Mouse Brain
Htt was immunoprecipitated with mouse monoclonal Htt antibody and
probed with rabbit polyclonal Htt BKP1 antibody (top right panel). The
input for each protein (left panels) and resulting immunoprecipitation
are shown (right panels). The lower molecular weight band in the PKM2
immunoprecipitation is an immunoglobulin (IgG) band. GAPDH is
included as a positive control. PARP is included as a negative control.
doi:10.1371/journal.pgen.0030082.g005
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Huntingtin Interactomeproteins that can be validated by assays based upon genetic
interaction and physical association in mammalian tissues
relevant to HD pathology.
Most speciﬁc molecular mechanisms proposed for Htt-
mediated pathogenesis can, in principle, be attributed to a
direct interaction between Htt and a protein component (or
components) of a given pathway. Consistent with this
assertion, we demonstrate here that a large set of Htt-
interacting proteins is highly enriched for genetic modiﬁers
of Htt-mediated neurodegeneration. Currently, there are
efforts directed toward discovering genetic modiﬁers of
human HD. Since the modiﬁers reported here were ﬁrst
discovered in screens performed with mammalian genes and
proteins and subsequently validated in Drosophila, it would be
of interest to determine whether human gene variants
encoding similar proteins and pathway act can act as
modiﬁers in human neurodegeneration.
Materials and Methods
Y2H screens. Automated screens were done as described in
LaCount et al. [31]. Brieﬂy, haploid yeast expressing Htt-bait fusion
proteins were grown in liquid medium in 96-well plates. Aliquots of
yeast of the opposite mating type expressing prey libraries were
added to each well and allowed to mate overnight. Matings were
plated on medium selecting for diploids, the expression of the
auxotrophic markers fused to the cDNA inserts and to the activity of
the metabolic reporter genes ADE2 and HIS3 [32,61]. cDNA prey
inserts from yeast that grew under selection were PCR-ampliﬁed and
sequenced. Identities of prey inserts were determined by BLAST
comparison against the National Center for Biotechnology (NCBI)
RefSeq database (http://www.ncbi.nlm.nih.gov). All reported interac-
tions were veriﬁed by recovering prey plasmids from positive
colonies, transforming these into yeast strains expressing Htt baits
and reconﬁrming the ADEþ, HISþ phenotype. Beta-galactosidase
measurements were performed according to manufacturer’s direc-
tions (Pierce, http://www.piercenet.com). Control yeast strains carry-
ing Htt bait and prey plasmids without an insert were used as
baseline. The Htt 55 Q bait had slightly higher background levels than
the corresponding Htt 23 Q bait. Y2H interactor lists were ﬁltered to
remove promiscuous proteins. Additional yeast methods can be
found in Supporting Information.
MS. Htt-fragment-interacting proteins underwent TAP and were
identiﬁed by MS [62]. Afﬁnity-tagged Htt N-terminal fragments fused
to GST and 6 3 His were incubated with protein lysates prepared
from mouse and human tissues and cultured cells. After TAP,
proteins were digested with trypsin, desalted, and subjected to strong
cation exchange (CEX). CEX fractions were further separated by
reverse-phase HPLC and subjected to MS analysis by matrix-assisted
laser desorption/ionisation-time of ﬂight (MALDI)MS/MS and electro-
spray ionization MS/MS. MS/MS data were used for protein sequence
database searches by Mascot (Matrix Sciences, http://www.
matrixscience.com) [63,64]. All searches were performed against the
subset of either human or mouse proteins in the NCBInr protein
sequence database (HumanNR or MouseNR). The minimum peptide
score was set at 10, and the minimum peptide length was set to 5;
otherwise the default instrument-speciﬁc Mascot settings were used.
A variable cut-off was applied to proteins, which was dependent upon
the number of peptides identiﬁed for a given protein. For any
protein from which only one peptide was identiﬁed, a minimal
peptide score threshold of 60 was required. If two peptides were
identiﬁed, a threshold ion score of 50 was required, and for three
peptides an ion score of 40 was required. Any peptides observed in
control pull downs done with beads bound to TAP-tag alone were
excluded. A statistical method, based on comparison of a wide variety
of pull downs, was used to identify nonspeciﬁc interactors, which
were also excluded. To validate protein identiﬁcation subsequent to
the automated thresholding and initial ﬁltering, each remaining MS/
MS spectrum was manually inspected to ensure that there were no
spurious results matched by Mascot. Detailed MS and statistical
methods can be found online with Supporting Information.
Drosophila polyQ toxicity model and genetic screen. A Drosophila
polyQ toxicity model was generated using an N-terminal fragment of
the human HD cDNA that encodes the ﬁrst 336 amino acids of the
protein including a 128-Q expansion in exon 1. The construct was
cloned into the pUAST vector for generating transgenic lines [65].
This HD Drosophila model is most similar to the expanded version (82
Q) of the N171 mouse model, which shows abundant intranuclear
inclusions [66] and neuronal degeneration [67]. Expression of the
128-Q N-terminal Htt fragment in Drosophila leads to neurodegener-
ative phenotypes. In the eye, these phenotypes are evident both
externally and in the retina following expression using the glass
multimer reporter (GMR)-GAL4 driver (Figures 2 and 3). In the
nervous system, Elav-GAL4-directed expression of the transgene leads
to progressive impaired motor ability and reduced life span (Figure
3C). Also as in the N171-82Q mouse, intranuclear inclusions are
observed in Drosophila neurons expressing the 128-Q N-terminal Htt
fragment (unpublished data).
For the modiﬁer screen, females of the genotype y
1w
118; GMR-
GAL4/CyO; UAS:128QHtt[M64] were crossed to males from the mutant
strains. In cases where the mutation was on the X chromosome, the
cross was reversed. Crosses were incubated at 27 8C and 29 8Ct o
provide two different phenotypic readouts. Strains modifying the eye
phenotype were recrossed to verify the modiﬁcation. Only genes that
consistently showed modiﬁcation at different temperatures or using
different alleles were further analyzed. Potential modiﬁers behaving
as enhancers were tested for possible nonspeciﬁc eye phenotypes by
crossing them to control females of the genotype y
1w
118; GMR-GAL4/
CyO.
For scanning electron microscopy (SEM) images, ﬂies were crossed
at 29 8C and newly eclosed adults were aged for ﬁve days. Whole ﬂies
were dehydrated in ethanol, critical-point dried, and analyzed with a
JEOL JSM 6100 microscope. For parafﬁn sections of enhancers, ﬂies
were crossed at 25 8C and adults were aged for ﬁve days (for
suppressors, the crosses were done at 27 8C and the ﬂies were aged for
one day). Adult heads and torsos were ﬁxed in 4% formaldehyde/85%
ethanol/5% acetic acid, dehydrated, embedded in parafﬁn for vertical
semi-thin sections, and then stained with Hemathox.
For the climbing and survival assays, females of the genotype Elav-
GAL4; UAS:128QHtt[F27B] were crossed to males of the mutant
strains. Climbing assays were performed on 30 age-matched adult
virgin female ﬂies raised at 27 8C as described [68]. The ﬂies, placed in
a plastic vial, were tapped to the bottom of the vial, and the number
of ﬂies above a 5-cm line was counted after 18 seconds. A total of ten
trials were performed every 48 hours. Each climbing and survival
experiment was repeated three times.
Immunoprecipitation. Whole brains from wild-type or YAC128
mice were lysed in T-PER (Pierce) with protease inhibitors (Complete
Mini, Roche Applied Science, http://www.roche.com). Protein deter-
mination was carried out with the BCA method (Bio-Rad, http://www.
bio-rad.com). Lysate (500 lg, 0.7 ml T-PER with protease inhibitors)
were precleared with mouse IgG beads (Sigma A6531, http://www.
sigmaaldrich.com) and immunoprecipitated with monoclonal Htt
antibody (5 ll, Chemicon 2166, http://www.chemicon.com) by
incubating overnight at 4 8C and then with protein G (40 ll,
Amersham 17-0618-01, http://www.amersham.com). Beads were
washed 53with TBS/0.05% Tween, sample was eluted with 13sample
buffer (Invitrogen, http://www.invitrogen.com) and then resolved
using 4%–12% Bis-Tris precast gels (Invitrogen). Western blot was
preformed, and blots were probed with rabbit antibody to USP9X
(1:200, Abcam 19879, http://www.abcam.com), Cullin 2 (1:500, Abcam
1870), CACNA2D1 (1:200, Sigma CS105), Htt BKP1 (1:500), PARP
(1:300, BioMol SA253, http://www.biomol.com), mouse monoclonal
GAPDH (1:100, Chemicon MAB374), STX1A (1:1000, Synaptic
Systems, 11001, http://www.sysy.com), SNAP25 (1:1000, Santa Cruz
Biotechnology SC-7539, http://www.scbt.com/), goat antibody PKM2
(1:500, Abcam 6191), and PSMC2 (1:1000, GeneTex 23322, http://www.
genetex.com).
Supporting Information
Figure S1. Puriﬁed Htt Exon 1 Bait
Puriﬁed bait protein from the ﬁrst and second puriﬁcation steps was
separated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and silver stained. The presence of glutathione
S-transferase (GST) and Htt in the bands was conﬁrmed by matrix-
assisted laser desorption/ionisation-time of ﬂight MS and Western
blotting (not shown). The predicted size of the GST-Htt fusion
product is 53 kDa. We were unable to determine the difference in the
two GST-Htt bands by MS; they may represent expanded (48 Q) and
wild-type (22 Q) Htt fragments. The band at 28 kDa represents GST
and likely occurs from cleavage of the fusion product between the
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Huntingtin InteractomeGST and the bait as we saw a band of this size with numerous
heterologous puriﬁed baits.
Found at doi:10.1371/journal.pgen.0030082.sg001 (575 KB PDF).
Figure S2. Saturation of Y2H Searches with Htt Baits
Only searches with N-terminal baits (amino acid 1–90, 23 Q; amino
acid 1–90, 55 Q; amino acid 1–450, 23Q; amino acid 1–450, 55 Q) that
gave at least one positive were included in the analysis. The x-axis
indicates numbers of screens performed. The y-axis shows the novel
discoveryindexforpreyproteins(e.g.,avalueof0.3indicatesthat30%
of the preys seen in a search were not seen in a prior screen). A peak
near 525 searches corresponds to introduction of new prey libraries.
Found at doi:10.1371/journal.pgen.0030082.sg002 (529 KB PDF).
Figure S3. Suppressors of Fly Eye Phenotype
Retinal sections of day-1 control ﬂies cultured at 27 8C expressing the
gene that encodes expanded N-terminal Htt (GMR-GAL4/þ;
UAS:128Qhtt[M64]/þ) (B) show a severe degenerative phenotype when
compared to (A) GMR-GAL4 controls of the same age and cultured at
the same temperature. The phenotype consists of a shortening (see
arrow) and detachment of the retina, as well as the presence of
vacuoles in the retina. The Htt-induced phenotype can be suppressed
by (C) reduced levels of armadillo (PflacWgarm
G0234; GMR-GAL4/þ;
UAS:128Qhtt[M64]/þ), (D) reduced levels of hu li tai shao (GMR-GAL4/
PflacWghts
k06121; UAS:128Qhtt[M64]/þ), (E) reduced levels of M6 (GMR-
GAL4/þ; UAS:128Qhtt[M64]/PfGT1gM6
BG00390), (F) reduced levels of
kinesin heavy chain (GMR-GAL4/b
1pr
1Khc
8; UAS:128Qhtt[M64]/þ), (G)
reduced levels of peanut (GMR-GAL4/PfSUP pr P-gpnut
KG00478;
UAS:128Qhtt[M64]/þ), (H) reduced levels of 14-3-3e (GMR-GAL4/þ;
UAS:htt[M64]/14-3-3e
j2b10), (I) reduced levels of G protein I a-subunit
65A (GMR-GAL4/; UAS:128Qhtt[M64]/PfSUPor-PgG-ia65A
KG01907ry
506),
(J) reduced levels of Itp-r83A (GMR-GAL4/þ; UAS:128Qhtt[M64]/
PfPZgItp-r83A
05616ry
506), (K) over-expression of Src oncogene at 42A
(GMR- GAL4/PfEPgy2gSrc42A
EY08937; UAS:128Qhtt[M64]/þ), (L) reduced
levels of clathrin heavy chain (Chc
4/þGMR-GAL4/þ; UAS:128Qhtt[M64]/
þ), (M) reduced levels of soluble N-ethylmaleimide-sensitive factor
attachment protein (GMR-GAL4/þ; UAS:128Qhtt[M64]/SNAP
M4), (N)
reduced levels of STX1A (GMR-GAL4/þ; UAS:128Qhtt[M64]/
ry
506PfPZgSyx1A
06737), (O) reduced levels of Rpt1 (GMR-GAL4/
PfPZgRpt1
05643cn1; UAS:128Qhtt[M64]/þ), (P) reduced levels of Eip75B
(GMR-GAL4/þ; UAS:128Qhtt[M64]/PfPZgEip75B
07041), (Q) reduced lev-
els of myocyte enhancing factor 2 (GMR-GAL4/Df(2R)X1,Mef2
X1;
UAS:128Qhtt[M64]/þ), (R) reduced levels of crooked legs (GMR-
GAL4/PfEPgy2gcrol
EY08953), (S) reduced levels of Glycerol 3 phos-
phate dehydrogenase (GMR-GAL4/Al
1Gpdh
n1–4; UAS:128Qhtt[M64]/þ),
(T) reduced levels of Pdsw (GMR-GAL4/PfPlacZgPdsw
k10101;
UAS:128Qhtt[M64]/þ), and (U) reduced levels of porin (GMR-GAL4/
pfPlacWgporin
k05123; UAS:128Qhtt[M64]/þ) and reduced levels of
CG12455 (GMR-GAL4/PfSUP or-PgCG12455
KG00260;U A S :
128Qhtt[M64]/þ). These mutations decrease the vacuolization and
increase the retinal thickness as well as virtually eliminating the
retinal detachment.
Found at doi:10.1371/journal.pgen.0030082.sg003 (2.7 MB PDF).
Figure S4. Enhancers of Fly Eye Phenotype
(A) Age-matched controls cultured at the same temperature (GMR-
GAL4/þ).
(B) Retinal sections of day 5 ﬂies expressing N-terminal 128-Q htt
(GMR-GAL4/þ; UAS:128Qhtt[M64]/þ) cultured at 25 8Cs h o wa
degenerative phenotype. The phenotype consists of a shortening
(arrow), vacuolization, and detachment of the retina. This phenotype
can be enhanced by (C) reduced levels of CAP (GMR-GAL4/PfSUPor-
PgCAP
KG00083; UAS:128Qhtt[M64]/þ), (D) reduced levels of CLIP-190
(GMR-GAL4/PfSUPor-PgCLIP-190
KG06490; UAS:128Qhtt[M64]/þ), (E) re-
duced levels of LaminC (GMR-GAL4/PfPTTor-GBgLamC
G00158;
UAS:128Qhtt[M64]/þ), (F) overexpression of M6 (GMR-GAL4/þ;
UAS:128Qhtt[M64]/PfEPgy2gM6
EY07032), (G) reduced levels of zipper
(GMR-GAL4/PfPZgzip
02957; UAS:128Qhtt[M64]/þ), (H) reduced levels of
short stop (GMR-GAL4/PfFRT(w
hs)gG13 shot
3; UAS:128Qhtt[M64]/þ), (I)
overexpression of 14-3-3e (GMR-GAL4/þ; UAS:128Qhtt[M64]/14-3-3e
ScerUASc.Ca), (J) overexpression of 14-3-31 (GMR-GAL4/ PfEPgy2g14-3-
31
EY03325; UAS:128Qhtt[M64]/þ), (K) overexpression of G-ia65A (GMR-
GAL4/ þ; UAS:128Qhtt[M64]/PfEPgy2gG-ia65A
EY10355), (L) overexpres-
sion of Itp-r83A (GMR-GAL4/ þ; UAS:128Qhtt[M64]/PfEPgy2gItp-
r83A
EY02522), (M) reduced levels of Lachesin (GMR-GAL4/PfPTT-
un1gLac
G00044; UAS:128Qhtt[M64]/þ), (N) reduced levels of Src oncogene
at 42A (GMR-GAL4/PflacWgSrc42A
k10108; UAS:128Qhtt[M64]/þ), (O)
overexpression of soluble NSF-attachment protein (GMR-GAL4/þ;
UAS:128Qhtt[M64]/UAS-S102C#2D), (P) overexpression of Syntaxin1A
(GMR-GAL4/þ; UAS:128Qhtt[M64]/PfEPgSyx1A
EP3215), (Q) reduced lev-
els of Aspartyl b-hydroxylase (GMR-GAL4/PfSUPor-PgAsph
KG09881;
UAS:128Qhtt[M64]/þ), (R) reduced levels of Dynein heavy chain 64C
(GMR-GAL4/þ; UAS:128Qhtt[M64]/PfSUPor-PgDhc64C
KG08838), (S) re-
duced levels of fat facets (GMR-GAL4/þ; UAS:128Qhtt[M64]/faf
Bx4), (T)
overexpression of Rpt1 (GMR-GAL4/PfEPgRpt1
EP2153;
UAS:128Qhtt[M64]/þ), (U) reduced levels of crooked legs (GMR-GAL4/
PfPZgcrol
04418; UAS:128Qhtt[M64]/þ), (V) reduced levels of Phosphogluc-
onate isomerase (GMR-GAL4/Pgi
nNC1; UAS:128Qhtt[M64]/þ), (W) reduced
levels of RhoGAP92B (GMR-GAL4/PfUAS-RhoGAP92B-dsRNAg2.2;
UAS:128Qhtt[M64]/þ), (X) reduced levels of Unc-76 (PflacWgUnc-
76
G0423a; GMR-GAL4/þ; UAS:128Qhtt[M64]/þ), and (Y) overexpression
of CG12455 (GMR-GAL4/PfEPgy2gCG12455
EY09750; UAS:128Qhtt[M64]/
þ). These mutations do not cause an abnormal eye phenotype in
control ﬂies carrying the GMR-GAL4 driver without the
UAS:128Qhtt[M64] transgene (unpublished data). However, when
combined with 128-Q htt, they lead to further decrease in retinal
thickness and in some cases increased retinal detachment and
vacuolization.
Found at doi:10.1371/journal.pgen.0030082.sg004 (2.8 MB PDF).
Table S1. Primary List of Peptides Identiﬁed in Pull Downs
Y indicates peptides that were manually validated and conﬁrmed by
inspection of the MS spectra; A refers to ambiguous peptides that
could not be conclusively identiﬁed by manual validation of the MS
spectra.
Found at doi:10.1371/journal.pgen.0030082.st001 (3.4 MB XLS).
Table S2. Primary List of Gene Sequences Identiﬁed from Y2H
Positives with Htt-Fragment Baits
*The total number of unique interacting proteins refers to the
number of unique gene sequences identiﬁed in a database of positives
from nearly .250,000 high-throughput random Y2H searches
performed at Prolexys Pharmaceuticals (http://www.prolexys.com).
Found at doi:10.1371/journal.pgen.0030082.st002 (580 KB DOC).
Table S3. Sequences of Positives Identiﬁed in Y2H Searches
Search ID is an identiﬁer given each Y2H mating event (see Materials
and Methods). Positive ID is a unique identiﬁer given to each positive
colony picked in Y2H searches. RefSeq ID, Gene Symbol, and Entrez
Gene ID refer to gene designations in the NCBI database (http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db¼gene). E_VALUE_EXP is the
negative log of the E value produced by the highest scoring BLAST hit
and has a maximum of 180 (corresponds to E value of 10E
 180 or less).
Amino acid coordinates of HD baits are indicated relative to
NP_002102. Q-length repeats are shown in parentheses. HD bait
sequences may be represented multiple times if more than one search
generated positives. High-throughput sequencing was performed
unidirectionally for identiﬁcation purposes and does not necessarily
represent the entirety of the clone. *Search ID 14291 (HD bait 1116–
1196) was identiﬁed in a search using a complex bait library rather
than individual bait clone.
Found at doi:10.1371/journal.pgen.0030082.st003 (3.2 MB XLS).
Table S4. Drosophila Orthologs of Human Genes Tested in the Fly HD
Strain
Found at doi:10.1371/journal.pgen.0030082.st004 (98 KB DOC).
Table S5. Drosophila Modiﬁers with Only One Conﬁrmed Modiﬁca-
tion Result
*Genes tested in Drosophila prior to statistical ﬁltering; E, Enhancer; S,
Suppressor
Found at doi:10.1371/journal.pgen.0030082.st005 (73 KB DOC).
Accession Numbers
The National Center for Biotechnology Information (NCBI) (http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db¼Protein) accession num-
bers for MS studies (RefSeq) are: NP_000302.1, NP_000382.3,
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Huntingtin InteractomeNP_000524.3, NP_000602.1, NP_000708.1, NP_001019645,
NP_001367.2, NP_001377.1, NP_001419.1, NP_001753.1,
NP_001779.2, NP_001834.2, NP_001853.2, NP_001854.1,
NP_001907.2, NP_001914.2, NP_001951.2, NP_001990.1,
NP_002046.1, NP_002064.1, NP_002065.1, NP_002102.4,
NP_002329.2, NP_002536.1, NP_003033.2, NP_003124.1,
NP_003156.1, NP_003170.1, NP_003356.2, NP_003357.2,
NP_003365.1, NP_003366.2, NP_003696.2, NP_004246.1,
NP_004309.2, NP_004364.2, NP_004365.1, NP_004484.1,
NP_004491.1, NP_004539.1, NP_004542.1, NP_004543.1,
NP_004594.1, NP_004850.1, NP_004993.1, NP_004996.1,
NP_004997.4, NP_005156.1, NP_005264.2, NP_005268.1,
NP_005653.3, NP_005736.3, NP_005995.1, NP_006046.1,
NP_006279.2, NP_006308.3, NP_006576.2, NP_006810.1,
NP_006830.1, NP_008839.2, NP_009034.2, NP_009204.1,
NP_031407.2, NP_031457.1, NP_031464.1, NP_031669.2,
NP_031736.1, NP_031773.1, NP_031887.2, NP_031959.1,
NP_032246.2, NP_032518.1, NP_032644.2, NP_033012.1,
NP_033033.1, NP_033321.1, NP_033332.1, NP_033333.2,
NP_033441.1, NP_033805.1, NP_033851.1, NP_033914.1,
NP_034053.1, NP_034078.1, NP_034438.1, NP_034442.1,
NP_034715.1, NP_034829.1, NP_034944.1, NP_035229.2,
NP_035253.1, NP_035523.1, NP_035558.1, NP_035824.1,
NP_035825.1, NP_036288.2, NP_036560.1, NP_036611.2,
NP_038709.1, NP_057049.3, NP_057223.1, NP_057606.1,
NP_058084.2, NP_060064.2, NP_061359.2, NP_062681.1,
NP_065593.1, NP_066268.1, NP_067541.1, NP_075553.1,
NP_077128.2, NP_077173.1, NP_077725.1, NP_077745.2,
NP_079589.1, NP_079612.1, NP_079634.1, NP_079683.2,
NP_080175.1, NP_080720.1, NP_080971.2, NP_080979.1,
NP_084501.1, NP_114080.2, NP_149124.2, NP_443106.1,
NP_444427.1, NP_536846.1, NP_536849.1, NP_542970.1,
NP_570824.1, NP_598429.1, NP_613063.1, NP_619621.1,
NP_659409.2, NP_663493.1, NP_663589.2, NP_766024.1,
NP_776169.2, NP_796376.2, NP_849209.1, NP_976218.1,
XP_128725.4, XP_131103.3, XP_203393.2, and XP_622887.1.
The NCBI (GeneID) (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼gene) accession numbers for Y2H studies are: 120, 161, 323,
1315, 1387, 1499, 1759, 1778, 1785, 2597, 3064, 3092, 3093, 3275, 3329,
3338, 3839, 4209, 4361, 4790, 5033, 5295, 5296, 5315, 5468, 5493, 5710,
5753, 6670, 6721, 6829, 6867, 7430, 7529, 7644, 7692, 7704, 7802, 8065,
8239, 8453, 8462, 8503, 8539, 9093, 9330, 9611, 9638, 9810, 9818, 9901,
9938, 10010, 10133, 10422, 10456, 10458, 10464, 10540, 10580, 10906,
10915, 11177, 11193, 23116, 23328, 23332, 23348, 23360, 23380, 23609,
23613, 23641, 25764, 26578, 27068, 28969, 29062, 29072, 29993, 51061,
51322, 51586, 51593, 51667, 55219, 55660, 55704, 55735, 56254, 57489,
57509, 57522, 57616, 63908, 79027, 79813, 80254, 83478, 84936,
128866, 134218, 139818, 152789, and 171392.
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